Gynecologic Cancer News

Olaparib Treatment May Improve Health-Related Quality of Life in Germline BRCA1/2-Mutated Ovarian Cancer

Olaparib Treatment May Improve Health-Related Quality of Life in Germline BRCA1/2-Mutated Ovarian Cancer

Olaparib, may help to improve duration of good quality of life and quality-adjusted progression-free survival in germline BRCA1/2-mutated ovarian cancer.

USPSTF Updates Its Recommendations for Cervical Cancer Screening

USPSTF Updates Its Recommendations for Cervical Cancer Screening

The US Preventive Services Task Force conducted a review of trials and cohort studies to support an update of its cervical cancer screening recommendations for women ages 21 to 65 and older.

Copy Number Abnormalities May Inform Survival, Drug Resistance

Copy Number Abnormalities May Inform Survival, Drug Resistance

For cancers associated with numerous copy number changes, it is difficult to assign disease classifiers and identify useful targets for drug development.

Aspirin, Non-Aspirin NSAID-Use May Improve Survival Outcomes in Ovarian Cancer

Aspirin, Non-Aspirin NSAID-Use May Improve Survival Outcomes in Ovarian Cancer

Previous studies have suggested that analgesic medicine use may have a protective effect for patients with ovarian cancer.

Could HPV Testing Take the Place of the Pap for Cervical Cancer Screening?

Could HPV Testing Take the Place of the Pap for Cervical Cancer Screening?

The confirmation of a positive HPV test appeared to be more predictive of a grade 2 or 3 cervical lesion than cytology screening alone.

Pembrolizumab FDA-Approved for the Treatment of Advanced Cervical Cancer

Pembrolizumab FDA-Approved for the Treatment of Advanced Cervical Cancer

Pembrolizumab is the first anti-PD-1 therapy approved for the treatment of advanced cervical cancer.

Post-Oophorectomy Estrogen Therapy May Not Increase Breast Cancer Risk in BRCA1 Carriers

Post-Oophorectomy Estrogen Therapy May Not Increase Breast Cancer Risk in BRCA1 Carriers

It was suggested that estrogen alone may have a protective effect, decreasing the risk of breast cancer by 8% with every year of use.

Ovarian Cancer Vaccine Shows Promise

Ovarian Cancer Vaccine Shows Promise

The researchers enrolled 25 platinum-pretreated, immunotherapy-naïve patients with recurrent advanced epithelial ovarian cancer (EOC) for the trial.

Highly Selective, First-in-Class CDK4 Inhibitor Promising in Ovarian Cancer

Highly Selective, First-in-Class CDK4 Inhibitor Promising in Ovarian Cancer

Mice treated with 2-94 had few or no signs of lymphopenia or neutropenia, common adverse events associated with palbociclib.

Pembrolizumab: Cost-Effective for Recurrent, MSI-H Endometrial Cancer

Pembrolizumab: Cost-Effective for Recurrent, MSI-H Endometrial Cancer

Per-cycle, PLD cost $2509, bevacizumab cost $7585, and pembrolizumab cost $9026.

Bevacizumab Plus Chemotherapy Prolongs PFS in Endometrial Cancer With p53 Null Status

Bevacizumab Plus Chemotherapy Prolongs PFS in Endometrial Cancer With p53 Null Status

p53 mutational status may be a viable strategy upon which to base the course of therapy.

Adjuvant Chemotherapy Non-Inferior to Chemoradiotherapy in Cervical Cancer

Adjuvant Chemotherapy Non-Inferior to Chemoradiotherapy in Cervical Cancer

There were no significant differences in patterns of recurrence in the chemotherapy vs CCRT groups.

Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma

Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma

Researchers randomly assigned 74 patients to receive everolimus plus letrozole daily or tamoxifen daily plus medroxyprogesterone daily on alternating weeks.

Antidepressants May Not Increase Ovarian Cancer Risk

Antidepressants May Not Increase Ovarian Cancer Risk

Previous epidemiological studies have indicated inconsistent results regarding the correlation between antidepressant use and ovarian cancer risk.

Survival Predictors in Ovarian Cancer and Current Immunotherapeutic Strategies

Survival Predictors in Ovarian Cancer and Current Immunotherapeutic Strategies

Researchers have found 3 major predictors for survival: tumor infiltrating leukocytes (TIL), programmed death-ligand 1 (PD-L1) expression, and mutational burden.

Current and Future Roles of PARP Inhibitors in Ovarian Cancer

Current and Future Roles of PARP Inhibitors in Ovarian Cancer

Ovarian cancer risk is known to be increased by BRCA1 and BRCA2 gene mutations, but recent developments have led researchers to believe there are several genes involved in homologous recombination-mediated DNA damage.

FDA Approves Bevacizumab-awwb as First Biosimilar for Anticancer Therapy

FDA Approves Bevacizumab-awwb as First Biosimilar for Anticancer Therapy

Bevacizumab-awwb is a recombinant IgG1 monoclonal antibody that works by binding to vascular endothelial growth factor (VEGF) and inhibits angiogenesis.

Rucaparib May Prolong PFS in Ovarian Cancer Responsive to Platinum Chemotherapy

Rucaparib May Prolong PFS in Ovarian Cancer Responsive to Platinum Chemotherapy

Eligible patients had platinum-sensitive malignancies, had at least 2 previous platinum-based therapies, and had reached complete or partial response to the most recent platinum-based regimen.

First-Line Dose-Dense Chemo Fails to Prolong PFS in Ovarian Cancer

First-Line Dose-Dense Chemo Fails to Prolong PFS in Ovarian Cancer

First-line treatment failed to improve progression-free survival among women of European descent with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC).

Platinum Therapy Should Not Be Delayed in Ovarian Cancer Relapse

Platinum Therapy Should Not Be Delayed in Ovarian Cancer Relapse

Researchers examined the differences in outcomes in patients with ovarian cancer who received platinum-based chemotherapy and non-platinum based chemotherapy after relapse.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Cancer Therapy Advisor Articles